NCT02764554View on ClinicalTrials.gov

Post-Marketing Surveillance of Lenvima in Korean Patients

CompletedOBSERVATIONAL

Enrollment

132

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

September 29, 2021

Study Completion Date

September 29, 2021

Conditions

Differentiated Thyroid Carcinoma (DTC)

Trial Locations (32)

Unknown

Eisai Trial Site #18, Anyang

Eisai Trial Site #30, Bundang

Eisai Trial Site #14, Goyang

Eisai Trial Site #27, Goyang

Eisai Trial Site #34, Goyang

Eisai Trial Site #21, Suwon

Eisai Trial Site #24, Yangsan

Eisai Trial Site #15, Busan

Eisai Trial Site #16, Busan

Eisai Trial Site #17, Busan

Eisai Trial Site #20, Busan

Eisai Trial Site #22, Busan

Eisai Trial Site #37, Busan

Eisai Trial Site #36, Daegu

Eisai Trial Site #4, Daegu

Eisai Trial Site #13, Gwangju

Eisai Trial Site #25, Incheon

Eisai Trial Site #26, Incheon

Eisai Trial Site #32, Incheon

Eisai Trial Site #19, Jeju City

Eisai Trial Site #1, Seoul

Eisai Trial Site #23, Seoul

Eisai Trial Site #29, Seoul

Eisai Trial Site #31, Seoul

Eisai Trial Site #33, Seoul

Eisai Trial Site #35, Seoul

Eisai Trial Site #38, Seoul

Eisai Trial Site #39, Seoul

Eisai Trial Site #8, Seoul

Eisai Trial Site #9, Seoul

Eisai Trial Site #12, Ulsan

Eisai Trial Site #6, Ulsan

All Listed Sponsors

lead

Eisai Korea Inc.

INDUSTRY

NCT02764554 - Post-Marketing Surveillance of Lenvima in Korean Patients | Biotech Hunter | Biotech Hunter